AAAAAA

   
Results: 1-25 | 26-49
Results: 1-25/49
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Authors: Wiseman, GA White, CA Sparks, RB Erwin, WD Podoloff, DA Lamonica, D Bartlett, NL Parker, JA Dunn, WL Spies, SM Belanger, R Witzig, TE Leigh, BR
Citation: Ga. Wiseman et al., Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, CR R ONC H, 39(1-2), 2001, pp. 181-194
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd)
Authors: Galanis, E Goldberg, R Reid, J Atherton, P Sloan, J Pitot, H Rubin, J Adjei, AA Burch, P Safgren, SL Witzig, TE Ames, MM Erlichman, C
Citation: E. Galanis et al., Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd), ANN ONCOL, 12(5), 2001, pp. 701-707
A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia
Authors: Tefferi, A Li, CY Reeder, CB Geyer, SM Allmer, C Levitt, R Michalak, JC Addo, F Krook, JE Witzig, TE Schaefer, PL Mailliard, JA
Citation: A. Tefferi et al., A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia, LEUKEMIA, 15(8), 2001, pp. 1171-1175
Thalidomide for previously untreated indolent or smoldering multiple myeloma
Authors: Rajkumar, SV Dispenzieri, A Fonseca, R Lacy, MQ Geyer, S Lust, JA Kyle, RA Greipp, PR Gertz, MA Witzig, TE
Citation: Sv. Rajkumar et al., Thalidomide for previously untreated indolent or smoldering multiple myeloma, LEUKEMIA, 15(8), 2001, pp. 1274-1276
CD4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predictspatient outcome
Authors: Ansell, SM Stenson, M Habermann, TM Jelinek, DF Witzig, TE
Citation: Sm. Ansell et al., CD4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predictspatient outcome, J CL ONCOL, 19(3), 2001, pp. 720-726
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
Authors: Dispenzieri, A Lacy, MQ Kyle, RA Therneau, TM Larson, DR Rajkumar, SV Fonseca, R Greipp, PR Witzig, TE Lust, JA Gertz, MA
Citation: A. Dispenzieri et al., Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival, J CL ONCOL, 19(14), 2001, pp. 3350-3356
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
Authors: Rajkumar, SV Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Therneau, TM Kyle, RA Greipp, PR Gertz, MA
Citation: Sv. Rajkumar et al., Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation, AM J HEMAT, 68(4), 2001, pp. 269-275
Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
Authors: Witzig, TE
Citation: Te. Witzig, Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma, CANC CHEMOT, 48, 2001, pp. S91-S95
Translocations involving the immunoglobulin heavy-chain locus are possibleearly genetic events in patients with primary systemic amyloidosis
Authors: Hayman, SR Bailey, RJ Jalal, SM Ahmann, GJ Dispenzieri, A Gertz, MA Greipp, PR Kyle, RA Lacy, MQ Rajkumar, SV Witzig, TE Lust, JA Fonseca, R
Citation: Sr. Hayman et al., Translocations involving the immunoglobulin heavy-chain locus are possibleearly genetic events in patients with primary systemic amyloidosis, BLOOD, 98(7), 2001, pp. 2266-2268
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death
Authors: Steensma, DP Gertz, MA Greipp, PR Kyle, RA Lacy, MQ Lust, JA Offord, JR Plevak, MF Therneau, TM Witzig, TE
Citation: Dp. Steensma et al., A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death, BLOOD, 97(8), 2001, pp. 2522-2523
Complete resolution of reflex sympathetic dystrophy with thalidomide treatment
Authors: Rajkumar, SV Fonseca, R Witzig, TE
Citation: Sv. Rajkumar et al., Complete resolution of reflex sympathetic dystrophy with thalidomide treatment, ARCH IN MED, 161(20), 2001, pp. 2502-2503
Prognostic value of bone marrow angiogenesis in multiple myeloma
Authors: Rajkumar, SV Leong, T Roche, PC Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Kyle, RA Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Prognostic value of bone marrow angiogenesis in multiple myeloma, CLIN CANC R, 6(8), 2000, pp. 3111-3116
Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents
Authors: Witzig, TE Timm, M Stenson, M Svingen, PA Kaufmann, SH
Citation: Te. Witzig et al., Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents, CLIN CANC R, 6(2), 2000, pp. 681-692
A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders
Authors: Witzig, TE Meyers, C Therneau, T Greipp, PR
Citation: Te. Witzig et al., A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders, LEUK LYMPH, 38(3-4), 2000, pp. 345
The Nasir/DeAngelis article reviewed
Authors: O'Neill, BP Witzig, TE
Citation: Bp. O'Neill et Te. Witzig, The Nasir/DeAngelis article reviewed, ONCOLOGY-NY, 14(2), 2000, pp. 242
Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
Authors: Wiseman, GA White, CA Stabin, M Dunn, WL Erwin, W Dahlbom, M Raubitschek, A Karvelis, K Schultheiss, T Witzig, TE Belanger, R Spies, S Silverman, DHS Berlfein, JR Ding, E Grillo-Lopezs, AJ
Citation: Ga. Wiseman et al., Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma, EUR J NUCL, 27(7), 2000, pp. 766-777
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
Authors: Rajkumar, SV Witzig, TE
Citation: Sv. Rajkumar et Te. Witzig, A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma, CANC TR REV, 26(5), 2000, pp. 351-362
Effect of complete response on outcome following autologous stem cell transplantation for myeloma
Authors: Rajkumar, SV Fonseca, R Dispenzieri, A Lacy, MQ Witzig, TE Lust, JA Larson, D Therneau, TM Kyle, RA Litzow, MR Greipp, PR Gertz, MA
Citation: Sv. Rajkumar et al., Effect of complete response on outcome following autologous stem cell transplantation for myeloma, BONE MAR TR, 26(9), 2000, pp. 979-983
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma
Authors: Gertz, MA Lacy, MQ Inwards, DJ Gastineau, DA Tefferi, A Chen, MG Witzig, TE Greipp, PR Litzow, MR
Citation: Ma. Gertz et al., Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma, BONE MAR TR, 26(1), 2000, pp. 45-50
The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
Authors: Witzig, TE
Citation: Te. Witzig, The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma, SEMIN ONCOL, 27(6), 2000, pp. 74-78
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.
Authors: Rajkumar, SV Gertz, MA Witzig, TE
Citation: Sv. Rajkumar et al., Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma., N ENG J MED, 343(13), 2000, pp. 972-973
Thalidomide in the treatment of relapsed multiple myeloma
Authors: Rajkumar, SV Fonseca, R Dispenzieri, A Lacy, MQ Lust, JA Witzig, TE Kyle, RA Gertz, MA Greipp, PR
Citation: Sv. Rajkumar et al., Thalidomide in the treatment of relapsed multiple myeloma, MAYO CLIN P, 75(9), 2000, pp. 897-901
Testicular lymphoma is associated with a high incidence of extranodal recurrence
Authors: Fonseca, R Habermann, TM Colgan, JP O'Neill, BP White, WL Witzig, TE Egan, KS Martenson, JA Burgart, LJ Inwards, DJ
Citation: R. Fonseca et al., Testicular lymphoma is associated with a high incidence of extranodal recurrence, CANCER, 88(1), 2000, pp. 154-161
Waldenstrom's macroglobulinaemia: a prospective study comparing daily withintermittent oral chlorambucil
Authors: Kyle, RA Greipp, PR Gertz, MA Witzig, TE Lust, JA Lacy, MQ Therneau, TM
Citation: Ra. Kyle et al., Waldenstrom's macroglobulinaemia: a prospective study comparing daily withintermittent oral chlorambucil, BR J HAEM, 108(4), 2000, pp. 737-742
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers
Authors: Halling, KC French, AJ McDonnell, SK Burgart, LJ Schaid, DJ Peterson, BJ Moon-Tasson, L Mahoney, MR Sargent, DJ O'Connell, MJ Witzig, TE Farr, GH Goldberg, RM Thibodeau, SN
Citation: Kc. Halling et al., Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers, J NAT CANC, 91(15), 1999, pp. 1295-1303
Risultati: 1-25 | 26-49